US 12,103,925 B2
Crystal and amorphous form of tolebrutinib, preparation method therefor, and use thereof
Xiaohong Sheng, Zhejiang (CN); Xiaoxia Sheng, Zhejiang (CN); and Yu Dai, Zhejiang (CN)
Assigned to HANGZHOU SOLIPHARMA CO., LTD., Hangzhou (CN)
Filed by HANGZHOU SOLIPHARMA CO., LTD., Zhejiang (CN)
Filed on Sep. 27, 2023, as Appl. No. 18/475,489.
Application 18/475,489 is a continuation of application No. PCT/CN2022/088495, filed on Apr. 22, 2022.
Claims priority of application No. 202110440752.X (CN), filed on Apr. 23, 2021; and application No. 202110479686.7 (CN), filed on Apr. 30, 2021.
Prior Publication US 2024/0018142 A1, Jan. 18, 2024
Int. Cl. C07D 471/04 (2006.01); A61K 31/437 (2006.01)
CPC C07D 471/04 (2013.01) [C07B 2200/13 (2013.01)] 24 Claims
 
1. Tolebrutinib Form 2 of the following formula,

OG Complex Work Unit Chemistry
wherein the XRPD pattern of Form 2 comprises at least four characteristic peaks at 2θ values of 7.8°±0.2°, 12.0°±0.2°, 18.5°±0.2°, 18.8°±0.2° and 22.9°±0.2°.